3-肼基-4-甲基苯甲酸盐酸盐 | 61100-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-肼基-4-甲基苯甲酸盐酸盐
• 中文别名: 3-肼基-4-甲基苯甲酸
• 英文名称: 3-hydrazino-4-methyl-benzoic acid hydrochloride
• 英文别名: 3-hydrazino-4-methylbenzoic acid hydrochloride；3-hydrazinyl-4-methylbenzoic acid;hydrochloride
• CAS: 61100-70-7
• 化学式: C₈H₁₀N₂O₂*ClH
• 分子量: 202.641
• InChiKey: BJDSGGGWVYBYLB-UHFFFAOYSA-N

物化性质

• 沸点：
  365.7±35.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.4
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Hydrazino-4-methylbenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Hydrazino-4-methylbenzoic acid
CAS number: 61100-70-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10N2O2
Molecular weight: 166.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-肼基-4-甲基苯甲酸盐酸盐 以94的产率得到3-(N'-tert-butoxycarbonyl-hydrazino)-4-methyl-benzoic acid
  参考文献：
  名称：

  5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS

  摘要：

  提供了基于5-成员杂环的p38激酶抑制剂。此外，还提供了基于吡唑和咪唑的p38激酶抑制剂，包括p38α和p38β激酶。还提供了包含这些化合物的药物组合物。还提供了这些化合物和组合物的使用方法，包括治疗、预防或缓解p38激酶介导的疾病和疾病的一个或多个症状的方法，包括但不限于炎症性疾病和疾病。

  公开号：

  US20130172352A1
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲酸 以66的产率得到3-肼基-4-甲基苯甲酸盐酸盐
  参考文献：
  名称：

  5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS

  摘要：

  提供了基于5-成员杂环的p38激酶抑制剂。此外，还提供了基于吡唑和咪唑的p38激酶抑制剂，包括p38α和p38β激酶。还提供了包含这些化合物的药物组合物。还提供了这些化合物和组合物的使用方法，包括治疗、预防或缓解p38激酶介导的疾病和疾病的一个或多个症状的方法，包括但不限于炎症性疾病和疾病。

  公开号：

  US20130172352A1

文献信息

• Anti-cytokine heterocyclic compounds
  申请人：Cogan Derek

  公开号：US20050256113A1

  公开（公告）日：2005-11-17

  Disclosed are compounds of formula (I) The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.

  揭示了式(I)的化合物。这些化合物抑制了参与炎症过程的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理条件，如慢性炎症性疾病。还揭示了制备这些化合物的方法以及包含这些化合物的药物组合物。
• 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS
  申请人：Novartis AG

  公开号：US20130172352A1

  公开（公告）日：2013-07-04

  Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

  提供了基于5-成员杂环的p38激酶抑制剂。此外，还提供了基于吡唑和咪唑的p38激酶抑制剂，包括p38α和p38β激酶。还提供了包含这些化合物的药物组合物。还提供了这些化合物和组合物的使用方法，包括治疗、预防或缓解p38激酶介导的疾病和疾病的一个或多个症状的方法，包括但不限于炎症性疾病和疾病。
• 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS
  申请人：Fryszman M. Olga

  公开号：US20050049288A1

  公开（公告）日：2005-03-03

  Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

  提供了基于5元杂环的p38激酶抑制剂。此外，还提供了基于吡唑和咪唑的p38激酶抑制剂，包括p38α和p38β激酶。还提供了含有这些化合物的制药组合物。还提供了使用这些化合物和组合物的方法，包括治疗、预防或缓解p38激酶介导的疾病和障碍的一个或多个症状，包括但不限于炎症性疾病和障碍。
• Substituted 1-phenyl-3-pyrazolecarboxamides active on neurotensin
  申请人：Sanofi

  公开号：US05723483A1

  公开（公告）日：1998-03-03

  The invention relates to new substituted 1-phenyl-3-pyrazolecarboxamides having a great affinity for human neurotensin receptors, to a process for preparing them and to pharmaceutical compositions containing them as active principles. More particularly, this invention relates to the discovery that the affinity for neurotensin receptors, especially human neurotensin receptors, is increased by substituting the phenyl group of 1-phenyl-3-pyrazolecarboxamide compounds with particular groups.

  本发明涉及新的取代的1-苯基-3-吡唑甲酰胺类化合物，其具有极强的与人类神经针对素受体的亲和力，以及制备它们的方法和含有它们作为活性成分的制药组合物。更具体地说，本发明是发现通过用特定基团取代1-苯基-3-吡唑甲酰胺化合物的苯基，可以增加其与神经针对素受体，特别是人类神经针对素受体的亲和力。
• Hydrazine derivative compounds as intermediates for preparing
  申请人：Sanofi

  公开号：US05936123A1

  公开（公告）日：1999-08-10

  This invention relates to intermediate compounds which are useful for making substituted 1-phenyl-3-pyrazolecarboxamides. The compounds of the invention have the formula: ##STR1## in which: R'.sub.2 and R'.sub.3 each independently represent a hydrogen, a (C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.8)cycloalkyl, a (C.sub.3 -C.sub.8)cycloalkylmethyl; or R'.sub.2 and R'.sub.3 together constitute a trimethylene, tetramethylene or pentamethylene group; R.sub.y is at position 4 or at position 5 and represents a group chosen from: cyano, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, benzyloxycarbonyl, sulpho, (C.sub.1 -C.sub.4)alkylsulphonylamino, (C.sub.1 -C.sub.4)alkylphenylsulphonylamino, carbamoyl, (C.sub.1 -C.sub.4)alkylcarboxamido; on condition that R'.sub.2 and R'.sub.3 do not simultaneously represent hydrogen and on condition that R'.sub.2 is other than methyl when R.sub.y is a sulpho group. The salts of the above compounds are also part of the invention.

  本发明涉及中间化合物，其用于制备取代的1-苯基-3-吡唑羧酰胺。本发明中的化合物具有以下结构式：##STR1## 其中：R'.sub.2和R'.sub.3各自独立地表示氢、(C.sub.1-C.sub.6)烷基、(C.sub.3-C.sub.8)环烷基、(C.sub.3-C.sub.8)环烷基甲基；或R'.sub.2和R'.sub.3共同构成三亚甲基、四亚甲基或五亚甲基基团；R.sub.y位于4位或5位，并表示从以下组中选择的一组：氰基、羧基、(C.sub.1-C.sub.4)烷氧羰基、苄氧羰基、磺酰基、(C.sub.1-C.sub.4)烷基磺酰氨基、(C.sub.1-C.sub.4)烷基苯基磺酰氨基、氨基甲酰基、(C.sub.1-C.sub.4)烷基羧酰胺；条件是R'.sub.2和R'.sub.3不能同时表示氢，并且当R.sub.y为磺酰基时，R'.sub.2不得为甲基。上述化合物的盐也是本发明的一部分。